Corporate News: Theriva Biologics Performance Overview
Theriva Biologics (ticker TOVX) experienced a decline of 4.76 % during the 24‑hour trading window that closed at 02:13 PM Central Europe on Thursday, 22 October 2026. At the time of reporting, the stock was trading at approximately USD 0.20 on major exchanges.
Current Market Snapshot
| Metric | Value |
|---|---|
| Shares Outstanding | 45.9 million |
| Market Capitalisation | USD 9.6 million |
| 24‑Hour Trading Volume | USD 142.2 k |
| 12‑Month Change | –13.04 % |
| 200‑Day Simple Moving Average | USD 0.24 |
| 52‑Week High | USD 0.85 (24 Oct 2025) |
| 52‑Week Low | USD 0.16 (23 Feb 2026) |
The recent slide in price reflects a broader trend among comparable biotech names, many of which have seen mixed fortunes in the same period.
Peer Comparison (Last 24 Hours)
| Company | Ticker | % Change | Current Price | Market Cap |
|---|---|---|---|---|
| Citius | CTXR | –5.26 % | USD 0.40 | USD 10.9 m |
| Astrotech | ASTC | +4.31 % | USD 5.08 | USD 11.0 m |
| Caring Brands | CABR | +3.29 % | USD 1.10 | USD 11.4 m |
| Sintx | SINT | +1.16 % | USD 1.74 | USD 11.5 m |
| In8bio | INAB | –4.39 % | USD 1.09 | USD 11.2 m |
While Astrotech, Caring Brands, and Sintx enjoyed modest gains, Citius and In8bio mirrored Theriva’s downward trajectory, underscoring volatility in the sector.
Strategic Focus of Theriva Biologics
Theriva Biologics, Inc. operates out of Rockville, United States, and concentrates on developing an adenovirus‑based platform for intravenous (IV), intravitreal, and antitumoral delivery. The platform is engineered to:
- Induce tumor‑cell death through targeted viral infection.
- Enhance delivery of co‑administered cancer therapies directly to tumor sites.
- Amplify and sustain anti‑tumor immune responses in patients.
The company’s technology aims to overcome key barriers in oncology therapeutics, including limited drug penetration and suboptimal immune engagement.
Historical Context
- IPO: 26 June 2006.
- Industry: Biotechnology, Health Care.
- Website: www.therivabio.com .
- Exchange: New York Stock Exchange (NYSE).
Theriva’s market cap and trading activity suggest it remains a small‑cap entity, rendering it sensitive to short‑term market sentiment and developments in its pipeline. Investors should monitor clinical milestones and regulatory updates that could pivot the company’s valuation trajectory.
The information presented above reflects market conditions as of the stated reporting time and is intended for informational purposes only. It does not constitute investment advice.
